中华老年医学杂志
中華老年醫學雜誌
중화노년의학잡지
Chinese Journal of Geriatrics
2014年
1期
26-28
,共3页
胡有东%李侠%赵庆娜%徐培敬
鬍有東%李俠%趙慶娜%徐培敬
호유동%리협%조경나%서배경
NF-κB%基因,p53%动脉粥样硬化%糖尿病,2型
NF-κB%基因,p53%動脈粥樣硬化%糖尿病,2型
NF-κB%기인,p53%동맥죽양경화%당뇨병,2형
NF-kappa B%Genes,p53%Atherosclerosis disease%Diabetes mellitus,type 2
目的 探讨核因子κB(NF-κB)、抑癌基因P53和mimecan/osteoglycin基因在老年外周动脉疾病(PAD)及合并2型糖尿病的关系. 方法 PAD患者共120例和同期健康体检者60例(对照组).根据临床诊断,将PAD患者分为PAD组60例,合并糖尿病组60例(合并糖尿病组),再按照Fontaine临床分级分别将PAD组分为Ⅰ级组15例、Ⅱ级组15例、Ⅲ级组15例、Ⅳ级组15例;合并糖尿病组分为Ⅰ级组14例、Ⅱ级组15例、Ⅲ级组16例、Ⅳ级组15例.采用酶联免疫法(ELISA)检测血清NF-κB、P53和mimecan水平. 结果 PAD组、合并糖尿病组、对照组NF-κB分别为(26.3±4.8)mg/L、(32.8±5.3)mg/L、(19.8±4.2)mg/L,P53分别为(2.5±1.1)mg/L、(3.4±1.3) mg/L、(1.4±0.8)mg/L,mimecan基因分别为(10.3±0.8)mg/L、(16.4±0.8)mg/L、(4.8±0.6)mg/L,合并糖尿病组NF-κB、P53和mimecan高于对照组和PAD组(均P＜0.05).PAD组中Ⅰ级、Ⅱ级、Ⅲ级、Ⅳ级患者NF-κB分别为(20.3±3.1)mg/L、(24.5±3.4)mg/L、(28.2±4.6)mg/L、(34.2±5.3)mg/L,P53分别为(2.2±1.8) mg/L、(2.6±1.8) mg/L、(3.3±1.9) mg/L、(3.7±2.7)mg/L,mimecan基因分别为(8.9±2.6) mg/L、(12.4±1.8)mg/L、(15.6±1.5)mg/L、(17.7±1.6)mg/L,各级NF-κB、P53和mimecan比较差异有统计学意义(均P＜0.05);合并糖尿病组中Ⅰ级、Ⅱ级、Ⅲ级、Ⅳ级患者NF-κB分别为(25.5±4.2)mg/L、(28.8±3.7)mg/L、(33.4±5.6)mg/L、(38.5±4.7)mg/L,P53分别为(2.5±1.1) mg/L、(2.9±1.0) mg/L、(3.7±1.2) mg/L、(4.6±1.3) mg/L,mimecan基因分别为(11.7±2.4) mg/L、(14.9±1.8) mg/L、(17.4±2.5) mg/L、(20.7±2.8) mg/L,不同分级NF-κB、P53和mimecan比较,差异有统计学意义(均P＜0.05).NF-κB、P53和mimecan随着PAD加重而升高(均P＜0.05). 结论 NF-κB、P53水平升高与mimecan水平及Fontaine分级升高有关.
目的 探討覈因子κB(NF-κB)、抑癌基因P53和mimecan/osteoglycin基因在老年外週動脈疾病(PAD)及閤併2型糖尿病的關繫. 方法 PAD患者共120例和同期健康體檢者60例(對照組).根據臨床診斷,將PAD患者分為PAD組60例,閤併糖尿病組60例(閤併糖尿病組),再按照Fontaine臨床分級分彆將PAD組分為Ⅰ級組15例、Ⅱ級組15例、Ⅲ級組15例、Ⅳ級組15例;閤併糖尿病組分為Ⅰ級組14例、Ⅱ級組15例、Ⅲ級組16例、Ⅳ級組15例.採用酶聯免疫法(ELISA)檢測血清NF-κB、P53和mimecan水平. 結果 PAD組、閤併糖尿病組、對照組NF-κB分彆為(26.3±4.8)mg/L、(32.8±5.3)mg/L、(19.8±4.2)mg/L,P53分彆為(2.5±1.1)mg/L、(3.4±1.3) mg/L、(1.4±0.8)mg/L,mimecan基因分彆為(10.3±0.8)mg/L、(16.4±0.8)mg/L、(4.8±0.6)mg/L,閤併糖尿病組NF-κB、P53和mimecan高于對照組和PAD組(均P＜0.05).PAD組中Ⅰ級、Ⅱ級、Ⅲ級、Ⅳ級患者NF-κB分彆為(20.3±3.1)mg/L、(24.5±3.4)mg/L、(28.2±4.6)mg/L、(34.2±5.3)mg/L,P53分彆為(2.2±1.8) mg/L、(2.6±1.8) mg/L、(3.3±1.9) mg/L、(3.7±2.7)mg/L,mimecan基因分彆為(8.9±2.6) mg/L、(12.4±1.8)mg/L、(15.6±1.5)mg/L、(17.7±1.6)mg/L,各級NF-κB、P53和mimecan比較差異有統計學意義(均P＜0.05);閤併糖尿病組中Ⅰ級、Ⅱ級、Ⅲ級、Ⅳ級患者NF-κB分彆為(25.5±4.2)mg/L、(28.8±3.7)mg/L、(33.4±5.6)mg/L、(38.5±4.7)mg/L,P53分彆為(2.5±1.1) mg/L、(2.9±1.0) mg/L、(3.7±1.2) mg/L、(4.6±1.3) mg/L,mimecan基因分彆為(11.7±2.4) mg/L、(14.9±1.8) mg/L、(17.4±2.5) mg/L、(20.7±2.8) mg/L,不同分級NF-κB、P53和mimecan比較,差異有統計學意義(均P＜0.05).NF-κB、P53和mimecan隨著PAD加重而升高(均P＜0.05). 結論 NF-κB、P53水平升高與mimecan水平及Fontaine分級升高有關.
목적 탐토핵인자κB(NF-κB)、억암기인P53화mimecan/osteoglycin기인재노년외주동맥질병(PAD)급합병2형당뇨병적관계. 방법 PAD환자공120례화동기건강체검자60례(대조조).근거림상진단,장PAD환자분위PAD조60례,합병당뇨병조60례(합병당뇨병조),재안조Fontaine림상분급분별장PAD조분위Ⅰ급조15례、Ⅱ급조15례、Ⅲ급조15례、Ⅳ급조15례;합병당뇨병조분위Ⅰ급조14례、Ⅱ급조15례、Ⅲ급조16례、Ⅳ급조15례.채용매련면역법(ELISA)검측혈청NF-κB、P53화mimecan수평. 결과 PAD조、합병당뇨병조、대조조NF-κB분별위(26.3±4.8)mg/L、(32.8±5.3)mg/L、(19.8±4.2)mg/L,P53분별위(2.5±1.1)mg/L、(3.4±1.3) mg/L、(1.4±0.8)mg/L,mimecan기인분별위(10.3±0.8)mg/L、(16.4±0.8)mg/L、(4.8±0.6)mg/L,합병당뇨병조NF-κB、P53화mimecan고우대조조화PAD조(균P＜0.05).PAD조중Ⅰ급、Ⅱ급、Ⅲ급、Ⅳ급환자NF-κB분별위(20.3±3.1)mg/L、(24.5±3.4)mg/L、(28.2±4.6)mg/L、(34.2±5.3)mg/L,P53분별위(2.2±1.8) mg/L、(2.6±1.8) mg/L、(3.3±1.9) mg/L、(3.7±2.7)mg/L,mimecan기인분별위(8.9±2.6) mg/L、(12.4±1.8)mg/L、(15.6±1.5)mg/L、(17.7±1.6)mg/L,각급NF-κB、P53화mimecan비교차이유통계학의의(균P＜0.05);합병당뇨병조중Ⅰ급、Ⅱ급、Ⅲ급、Ⅳ급환자NF-κB분별위(25.5±4.2)mg/L、(28.8±3.7)mg/L、(33.4±5.6)mg/L、(38.5±4.7)mg/L,P53분별위(2.5±1.1) mg/L、(2.9±1.0) mg/L、(3.7±1.2) mg/L、(4.6±1.3) mg/L,mimecan기인분별위(11.7±2.4) mg/L、(14.9±1.8) mg/L、(17.4±2.5) mg/L、(20.7±2.8) mg/L,불동분급NF-κB、P53화mimecan비교,차이유통계학의의(균P＜0.05).NF-κB、P53화mimecan수착PAD가중이승고(균P＜0.05). 결론 NF-κB、P53수평승고여mimecan수평급Fontaine분급승고유관.
Objective To explore the correlation of mimecan/osteoglycin withnuclear factor koppa B(NF-κB) and P53 in peripheral arterial disease (PAD) and PAD combined with type 2 diabetes in the elderly.Methods 120 patients with PAD and 60 healthy controls were enrolled in this study.PAD patients were divided into PAD group (n=60) and PAD combined with type 2 diabetes group (n =60) according to clinical diagnostic criteria.Patients in PAD group were divided into class Ⅰ (n=15),class Ⅱ (n=15),class Ⅲ (n=15) and class Ⅳ (n=15),and patients in PAD combined with type 2 diabetes group were divided to class Ⅰ (n=14),class Ⅱ (n=15),class Ⅲ (n=16) and class Ⅳ (n=15) according to Fontaine's classification.The levels of NF-κB,P53 and mimecan in peripheral blood were measured by enzyme-linked immunosorbent assay (ELISA).Results The levels of NF-κB,P53 and mimecan were significantly increased in PAD combined with type 2 diabetes group as compared with PAD and control groups [NF-κB..(32.8±5.3) mg/L vs.(19.8±4.2) mg/L,(26.3 ±4.8) mg/L; P53:(3.4±1.3) mg/Lvs.(2.5±1.1) mg/L,(1.4±0.8) mg/L; mimecan:(16.4 ±0.8) mg/L vs.(10.3±0.8) mg/L,(4.8±0.6) mg/L; all P＜0.05].There were significant differences in the levels of NF-κB,P53 and mimecan in class Ⅰ,class Ⅱ,class Ⅲ and class Ⅳ in PAD group [NF-κB:(20.3±3.1) mg/L,(24.5±3.4) mg/L,(28.2±4.6) mg/L and (34.2±5.3) mg/L; P53:(2.2 ±1.8) mg/L,(2.6±1.8) mg/L,(3.3±1.9) mg/L and (3.7±2.7) mg/L;mimecan (8.9±2.6) mg/L,(12.4±1.8) mg/L,(15.6±1.5) mg/L and (17.7±1.6) mg/L; all P ＜0.05].There were significant differences in the levels of NF-κB,P53 and mimecan in class Ⅰ,class Ⅱ,class Ⅲ and class Ⅳ in PAD group combined with type 2 diabetes group [NF-κB:(25.5±4.2) mg/L,(28.8±3.7) mg/L,(33.4±5.6) mg/L and (38.5±4.7) mg/L; P53:(2.5±1.1)mg/L,(2.9±1.0)mg/L,(3.7±1.2)mg/L and(4.6±1.3)mg/L; mimecan:(11.7±2.4)mg/L,(14.9± 1.8)mg/L,(17.4±2.5)mg/L and(20.7±2.8)mg/L; all P＜0.05].The levels of NF-κB,P53 and mimecan was increased with the aggravation of PAD (all P＜0.05).Conclusions The increased levels of NF-κB and P53 are correlated with the increase in mimecan level and Fontaine's classification.
